Soft-tissue sarcomas (STS) are an uncommon and heterogeneous group of malignancies that result in high mortality. Metastatic STS have very bad prognosis due to the lack of effective treatments. Dinaciclib is a model drug for the family of CDK inhibitors. Its main targets are cell cycle regulator CDK1 and protein synthesis controller CDK9. We present data supporting Dinaciclib ability to inactivate in vitro different STS models at nanomolar concentrations. Moreover, the different rhythms of cell death induction allow us to further study into the mechanism of action of the drug. Cell death was found to respond to the mitochondrial pathway of apoptosis. Anti-apoptotic Bcl-x L was identified as the key regulator of this process. Bcl-x L showed a slower decay curve after protein synthesis disruption that in tolerant cell lines was enough to delay apoptosis, as its action cannot be countered by the relative low levels of pro-apoptotic BH3 proteins BIM and PUMA. Combination of Dinaciclib with BH3-mimetics led to quick and massive apoptosis induction in vitro, but in vivo assessment was prevented due to liver toxicity. Additionally, Bcl-x L inhibitor A-1331852 also synergized with conventional chemotherapy drugs as Gemcitabine. Thus, Bcl-x L targeted therapy arises as a major opportunity to the treatment of STS.
Introduction
Soft-tissue sarcomas (STS) are a group of tumors derived from mesenchymal precursors with scarce incidence and rich variability (1) . Tumors arising from non-epithelial extraskeletal tissue are generally accounted as STS (2) . There has been much improvement in the understanding of the drivers of STS entities: (i) STSs driven by specific chromosome fusions leading to generation of anomalous transcription factors (like FUS-CHOP in myxoid liposarcoma) or chromatin remodelers (SS18-SSX in synovial sarcoma); (ii) STS that rely on specific mutations (KIT in gastrointestinal stromal tumors) and (iii) other STS driven by more complex genomic rearrangements (like leiomyosarcomas or some fibrosarcomas) (3, 4) . STS incidence is difficult to estimate due to their variability, and some reports claim that the usual figures could be underestimations (1, 5) . Clinical prognosis and therapeutic outcome is also highly variable in STS (2) . When it is possible, the complete clinical resection make full recovery achievable. However, almost half of the patients will develop metastatic disease. Five-year survival rates are still below 50 %. So, the weight of STS in total cancer death toll is clearly disproportionate to its incidence (4, 6) .
Thus, STS can benefit for new therapeutic approaches (6) . Among the molecular targeted drugs in development, the group of Cyclin-Dependent Kinases (CDKs) inhibitors is one of those concealing major interest (7) . CDKs constitute a wide family of Ser/Thr protein kinases that require binding with cyclins to act. This coupling enables a complex panorama of interactions that keep track on the activation/suppression of specific pathways during cell cycle (8) . Several CDK inhibitors have been identified and tested in vitro as anti-cancer agents (7, 9) . The initial aim of CDK inhibitor strategy was the disruption of cell cycle sequence-of-events in order to induce cell death (9, 10) .
But it was soon understood that CDKs exert more powerful effects over other processes of cell physiology like transcription regulation, RNA splicing or protein folding (9) .
Dinaciclib is a promising CDK inhibitor, extensively proved pre-clinically (11) . Its known affinities encompass CDK1 (IC 50 =3 nM), CDK2 (IC 50 =1 nM), CDK5 (IC 50 =1 nM) and CDK9 (IC 50 =4 nM) (12) . CDK2 is a key cell cycle regulator in meiosis but its significance in somatic cells is relative (8) . CDK5 role is less clear. It has been associated with neuronal metabolism via multiple interactions, including proteins from the cytoskeleton (13) . Most studies concerning Dinaciclib activity have been focused on the CDK1 control of mitotic entry and CDK9 regulation of gene transcription (14) (15) (16) .
CDK9-dependent down regulation of anti-apoptotic Bcl-2 family member Mcl-1 is commonly regarded as the main mechanism of action of this drug (17, 18) . Some Phase I clinical trials (mostly in pediatric leukemia) have also been performed with Dinaciclib.
Anti-cancer activity was found to be encouraging, but not sufficient for planning monotherapy treatments. Further use of Dinaciclib is thought to rely on combination therapies (14, 19, 20) .
Combination therapies constitute a hot spot in oncology research. It has become clear its benefits avoiding tumor evolution in favor of drug resistant phenotypes (21) . Moreover, combination therapies work better than monotherapy even in the absence of synergistic behavior (22) . BH3-mimetics are a new class of anti-cancer drugs particularly interesting for these combinations. They are aimed to disturb the balance of the different proteins of the Bcl-2 family, thus favoring apoptosis triggering (23, 24) . Alone, BH3mimetics have been successfully used in chronic lymphocytic leukemia since the FDA approval of Venetoclax (25) . BH3-mimetics work better when the cells are already undergoing an apoptotic signaling process that has been compensated by expression or activity changes in the Bcl-2 family of proteins. Cells became addicted to these compensative mechanisms creating then an Achilles' heel for cancer cells (24) . Recent screenings are showing that BH3-mimetics boost the cytotoxic potential of a panoply of chemicals, including CDK9 inhibitors (26) .
Our aim in the present study is to seek the suitability of Dinaciclib in a series of STS in vitro models as cell death inductor, fully characterizing the cellular response to treatment. We have found that Dinaciclib is capable of inducing cell death as single agent. The cellular context, particularly the Bcl-2 family balance, at every model is decisive for the precise behavior after Dinaciclib incubation. Our data support that Bclx L inhibition status is central for treatment tolerance. Moreover, Bcl-x L specific inhibitors synergize with Dinaciclib to avoid such tolerance.
Materials & Methods
Cell culture.
Cell lines ( Table 1) were cultured in RPMI-1640 supplemented with 10 % (v/v) heatinactivated FBS, 1 % (v/v) Penicillin-Streptomycin and 1 % (v/v) HEPES (Gibco). All cell lines were incubated in an AutoFlow NU-4750 Incubator (NuAire) at 37 °C in a humidified atmosphere of 5 % CO 2 in air. Otherwise specified, plasticware were purchased from Jet BioFil. Authenticity of the cell lines was routinely confirmed by STR profiling analysis done at qGenomics SL (Esplugues de Llobregat, Barcelona, Spain).
Exponential growing cells were used for all experiments. Depending on cell size and proliferation rates, 80,000-180,000 cells were seeded in 12-well plates (or 1-2 million cells in P100 dishes) and allowed to grow for 24 h prior to treatment. Cells were routinely observed and photographed by means of an IX70 inverted epifluorescence microscope (Olympus).
For 3D cultures, we seeded 80,000 cells mixed in 1:1 dilution of medium and Matrigel ® (Corning Inc.) in 24-well plates already coated with a solidified layer of pure Matrigel ® .
Cells were kept in these conditions for 72 h to allow microsphere formation prior to
Cell line
Origin Provider SW982
Synovial Sarcoma ATCC Immunofluorescence.
Cells ( Five million (5×10 6 ) SK-LMS-1 cells in 1:1 RPMI:Matrigel ® were subcutaneously (s.c.)
injected in the right dorsal flank of the mice. Tumor growth was followed by a caliper and volume was extrapolated using the formula vol=(L×l 2 )/2 were "L" refers to the major and "l" to the minor diameter measured. Drug treatments started when tumors reached a volume of approximately 100 mm 3 . Mice were blindly randomized into the different groups by using a 6-faced dice.
After the end of the experiment, tumors and organs of interest were extracted and fixed (27) .
Mice survival curves were analyzed using Prism (GraphPad Software Inc.).
Results
Dinaciclib induces cell death in STSs independently of CDK1 and CDK9 expression levels.
To have a base for inferring the response of STS to Dinaciclib, we analyzed the expression of CDK9, CDK1 and its partners Cyclin B1 and A2 in a series of cell lines representative of major groups of STS: synovial sarcoma SW982 and 1273-99, leiomyosarcoma SK-LMS-1 and SK-UT-1, myxoid liposarcoma 402-91 and 1765-92, dedifferentiated liposarcoma SW872 and myxofibrosarcoma HT-1080 ( Figure 1A) .
Protein expression was variable among the cell lines, from the rather homogenous 43 kDa (low band) of CDK9 to the more variable CDK1. SW872 expressed comparatively undetectable levels of CDK1 and its partners. However, the levels of the 55 kDa (high band) of CDK9 were among the highest.
The same set of cell lines was used to test the ability of Dinaciclib to impair cellular viability (read as WST-1 assay, Figure 1B) . SW982, SW872 and HT-1080 showed fewer decreases in viability at low concentrations, but at 27 nM differences among the cell lines were reduced. IC 50 calculations failed for SW872 and HT-1080 due to high disparity of the data (Supplementary Figure 1A) , Figure 1B) .
In order to confirm that Dinaciclib induced mitochondrial apoptosis we studied the translocation of pro-apoptotic protein Bax to the mitochondria (Figure 1E ) and the caspase-3 activation reporter PARP (Supplementary Figure 1C) . Dinaciclib potential as cell death inducer was conserved also in 3D tissue simulation.
402-91 cells embedded in a Matrigel ® matrix grew as microspheres. By treating the microspheres with Dinaciclib for 24 h prior staining with vital dye H-33342, we clearly observed a reduction of the size of the spheres but also the accumulation of bright pyknotic nuclei generated by apoptosis ( Figure 1F) .
Taken together, our results show the potential of Dinaciclib as inducer of apoptotic cell death in STS at nanomolar concentrations.
Bcl-x L interferes in Dinaciclib-induced apoptosis in sarcomas. (Figure 2A) .
Cells from the sensitive lines (like 1273-99) presented rare, if any, surviving colonies.
Additionally, we allowed those colonies to grow into sub-cultures that we dubbed Dinaciclib Resistant (DR). Those DR lines were newly challenged with 72 h incubation of Dinaciclib 25 nM. DRs from the tolerant group did not show any evident difference in behavior from the parental culture. But those derived from the sensitive cell lines appeared to have acquired a better fitness against the drug (Figure 2B) . Nevertheless, when different experiments were summed up there was no statistical significance in this trend to a reduced cell death induction (Figure 2C) .
Therefore, our data suggests that Dinaciclib exerts a long-term effect in cell viability with the additional value that surviving colonies do not show a strong selection towards drug resistance.
Bcl-x L interferes in Dinaciclib-induced apoptosis in sarcomas. (Figure 3A) .
For most proteins little variation among the cell lines was observed. However, other proteins did shown remarkable differences in expression between the two groups.
Tumor suppressor p53 was almost undetectable in Dinaciclib tolerant cells when compared with the responsive ones. In this regard, it is important to note that SK-LMS-1 cell line has been described as TP53 mutant (28) . SK-LMS-1 expressed also relatively low levels of p21 Waf1/Cip1 (p21) protein, a p53 target. Finally, CDK4 inhibitor p16 INK4a (p16) presented a pattern very similar to p53. If we compare this data with the study of cell cycle changes, we can see that only cell line SW982 presented a statistically significant arrest in G 2 /M phase ( Supplementary Figure 2A) . In any case, most of the Dinaciclib tolerant cell lines did share the same trend. To analyze the precise nature of this G 2 /M blockade we visualized treated and untreated cells immunolabelled for Ser10phosphorylated Histone H3 (p-H3) and p21. Our results confirmed that the arrest was not due to accumulation of mitotic events but rather to the arrest of cells in the G 2 phase (or in a tetraploid G 1 ). In concordance with the protein expression data p21 was not induced in SK-LMS-1 cells (Supplementary Figure 2B) . To complete the analysis, we found that senescence-related p16 translocated towards the nuclei in tolerant cell lines treated with Dinaciclib, in a way similar to the sensitive ones (whose signal was clearly more intense) (Supplementary Figure 2C) . Thus, tolerance to Dinaciclib seems to be linked to the generation of a partial G 2 arrest without a clear or sustained induction of senescence, as cells finally die in the following days (Figure 2A) .
Bcl-x L interferes in Dinaciclib-induced apoptosis in sarcomas. 1 8 Among the mitochondrial apoptotic control machinery, major differences were found in the small pro-apoptotic BH3-only proteins PUMA and BIM. Both were found comparatively over-expressed in Dinaciclib sensitive cell lines. Minor differences were also found in Noxa, BMF or Mcl-1 but with no correlation with the Dinaciclib response.
The major effect of Dinaciclib via inhibition of CDK9 is the interruption of mRNA transcription (17, 29) . On this basis, we analyzed how our main targets evolved upon Dinaciclib incubation (Figure 3B) . As expected, most of the proteins showed a radical decrease in expression after Dinaciclib incubation. In concordance with the data from (Figure 4B) . In time, the induced damage will force the cells to die (Figure 2A) .
To check the coherence of our hypothesis, we have reviewed the data presented by
Booher and co-workers in 2014 showing correlation between MCL1:BCL2L1 mRNA ratio and viability after 24 h 100 nM Dinaciclib treatment (18) . By reducing the 250 samples to the ones appertaining to STS, we still found a statistically significant correlation, meaning that those cell lines more depending on Mcl-1 were also prone to die after Dinaciclib (Supplementary Figure 3A) .
For experimental validation, we addressed the role of Mcl-1 in Dinaciclib-induced cell death by siRNA silencing (Supplementary Figure 3B) . Although Mcl-1 was successfully depleted, no major increase in cell death was observed in SW982 cells Figure 3C) . However, depleting Bcl-x L in Dinaciclib tolerant cell lines before Dinaciclib addition (Supplementary Figure 3D) clearly resulted in an increase of the detachment of cells (Figure 4C) . When cell death induction was quantified, the increase of cell death at 24 h of treatment was deemed statistically significant (Figure 4D ). Figure 4B & D) . Cytofluorometric measurement showed that both combinations synergized (27) in terms of apoptosis induction after 24 h of treatment at very low concentrations (Figure 5A-B) . Moreover, A-1331852 was more efficient than ABT-737. These results confirmed our operational hypothesis regarding Dinaciclib mechanism of action.
(Supplementary
The next logical step was trying the drug combination in vivo. Our first approaches were aimed to assess treatment toxicity and cell growth using Hsd:Athymic NudeFoxn1 nu mice. We tried different combination regimes of Dinaciclib and ABT-737 based on literature (18, 30) (Supplementary Figure 5A) , but we always observed liver toxicity linked to massive hepatocyte death (Figure 5C) . Moreover, human SK-LMS-1 showed a poor efficiency of nesting and growing as sub-cutaneous tumors in those mice (Supplementary Figure 5B) . In consequence, we moved to the more immunodepressed CB17.Cg-Prkdc scid Lyst bg-J /Crl mice trying a lower dosage of Dinaciclib (as it was able to kill the mice even as monotherapy) and A-1331852 instead of ABT-737 Figure 5C) . SK-LMS-1 cells grew better in these mice Figure 5D) , but an important percentage of tumors appeared as intraperitoneal masses despite being injected sub-cutaneously (Figure 5D ). Intra-peritoneal tumors grew by surrounding, engulfing and finally invading the kidney (Supplementary Figure 5E) . Those mice were excluded from the final experiments.

Final in vivo testing of anti-tumoral combined activity of both drugs was unsuccessful in terms of mice survival (Figure 5E) . The failure was allegedly due to a lack of overall effect of the drugs, as can be inferred for the unchanged mice weight (Supplementary   Figure 5F) . Summing up, we could not reach a therapeutic regime in which the drugs showed anti-tumor activity without induction of deadly toxicity.
Notwithstanding this set back, we sought to understand whether the key role of Bcl-x L in Dinaciclib-induced cell death was a particular feature or part of a more general behavior. Other groups have already shown a positive cooperation of BH3-mimetics with CDK inhibitors and anthracyclines (26, 31) . So, we tested another commonly used anti-tumor drug in STS therapy: nucleoside analogue Gemcitabine. Our results showed that A-1331852 synergized with Gemcitabine in terms of cell death induction after 48 h of combined treatment (Figure 5F) .
Taking together, our results unveil the specificities of cellular response to CDK inhibitor Dinaciclib and positively identify Bcl-x L as the key player of apoptosis induction in these systems. More pharmaceutical research will be required to achieve a safe way for clinical practice, probably through the development of new delivery methods or new molecules with reduced side-effects. Still, this question falls beyond the scope of our study.
Bcl-x L interferes in Dinaciclib-induced apoptosis in sarcomas. 
Discussion
Dinaciclib is one of the most promising compounds in the group of CDK inhibitors because is able to act by meddling in the progression of late steps of the cell cycle, the entry in mitosis, transcriptional regulation and even the unfolded protein response (15, 32, 33) . It has been studied in clinical trials on cancer entities such as acute leukemia and other pediatric malignancies (11, 14, 20) . Dinaciclib was well tolerated, but its therapeutic effect as single agent did not achieve any total remission. However, in several neoplasias it is considered a good candidate for combination therapies (7, 33, 34) ,
including BH3-mimetics (26) .
Here we present new data on Dinaciclib pre-clinical results in STS cell lines. Our results show that Dinaciclib is able, as single agent, to impede cell proliferation in a nanomolar
Bcl-x L interferes in Dinaciclib-induced apoptosis in sarcomas. 2 6 range ( Figure 1B) and to induce cell death at least in myxoid liposarcoma 402-91 and synovial sarcoma 1273-99 cells (Figure 1D) . Our model of 3D culture also proves that Dinaciclib is able to infiltrate and kill cells in solid tumors (Figure 1F) . These results align with previous pre-clinical reports that have also proved the utility of Dinaciclib in different tumor entities (16, 18, 33) . Moreover, our long-term studies after Dinaciclib removal showed that the deregulation induced by the drug was enough to promote a delayed death (five days after drug withdrawal) and that the remnant colonies did not develop an enhanced resistance to re-challenge ( Figure 2C) . The lack of reinforced tolerance to Dinaciclib in DR lines opens the gate to the establishment of repeated administrations or combination procedures (35, 36) .
To do so, a proper cell death mechanism characterization is paramount (37) . In this sense, our results proved that the main mechanism involved in Dinaciclib killing is the mitochondrial apoptotic pathway (Figure 1D-E and Supplementary Figure 1B-E) .
Other in vitro studies published with Dinaciclib also pointed to apoptotic mechanisms but they provided a less detailed characterization of the cell death (16, 17, 19) . Dinaciclib action involves two clearly different processes: cell cycle inhibition and alteration in protein production and homeostasis (9, 32) . The study of those cell lines more tolerant to
Dinaciclib is helpful as their delayed death allow us to observe other variables. Cell cycle profiling showed a trend to an arrest in G 2 -to-M transition that was only significant in SW982 ( Supplementary Figure 2A) . SW982 cells are also the only cell line able to induce an increase in p21 protein (Figure 3B and Supplementary Figure   2B ). Our data agreed to previous reports in other cancer entities, in which the cell cycle arrest was revealed when apoptosis was inhibited by Bax/Bak DKO (18) . But this mechanism may not be universal as most of our Dinaciclib tolerant cell lines did not reach statistically significant mitotic arrest. However, the sensitive cell lines indeed did increase their G 2 /M and postM (tetraploidy) phases when apoptosis was abrogated by z-VAD-fmk (data not shown). So, it appears that the effect on the cell cycle deregulation in our models may be an important contributor in the apoptotic triggering. Further research is needed to understand if other proteins (like p21) are required for G 2 arrest after CDK1 inhibition.
The role of cell cycle regulator p16 is intriguing. It is one of the multiple transcripts of the CDKN2A locus, all of them with key functions in the homeostasis of the cell cycle, tumor suppression, senescence and aging (38) (39) (40) (41) (42) . The expression of p16 is not directly regulated by p53 but rather by Jun-B and Ras via Ets-1/2 (38) . However, there are references cross-linking Ets-1/2 transcription factors with Bcl-2 family expression (43) (44) (45) (46) and even p53 activity (47) . In our settings, the sensitive cell lines 1273-99 and 402- Figure 2C ). Hence, there is supporting data to consider that expression levels of p16 could be linked to an apoptotic-permissive unbalance among the Bcl-2 family that enhances Dinaciclib sensitivity. As has been proved in other cancer entities, we consider interesting to explore the use of p16 as a predictive marker for cell cycle targeted therapies (39, 42) .
Dinaciclib causes a general depletion of protein content in the cell via RNA Polymerase II dephosphorylation with different impact depending on protein distinctive half-life (7, 9, 17, 18) . From our list of proteins of interest (Figure 3B) , Dinaciclib cytotoxicity because its expression drops drastically after treatment (17) (18) (19) .
Recently, a more comprehensive study from Inoue-Yamauchi and co-workers lead to a more complex panorama in which every member of the Bcl-2 family has a role in the apoptotic triggering (26) . For STS, the limited cohort from Booher and co-workers provides correlation between Dinaciclib sensitivity and Mcl-1/Bcl-x L ratio (Supplementary Figure 3A) . However, our data showed that Mcl-1 levels are already low in SW982 cells (Figure 3A) and quickly become almost undetectable upon Dinaciclib treatment in all cell lines (Figure 3B) . So, we envisaged a mechanistic hypothesis that put remnant Bcl-x L interaction with BIM and/or PUMA in the decision point of apoptosis triggering in STS cell lines (Figure 4A-B Figure 4C-D and Supplementary Figure 3B-C) .
Bcl-x L involvement as key mediator of apoptosis triggering has been previously described in several contexts including cell cycle alterations and other sarcoma entities (49) (50) (51) . Among the different Bcl-2 family interactions, Bcl-x L has strong affinity for pro-apoptotic BH3-only proteins PUMA and BIM (49, 50, 52, 53) . BH3-mimetics are a new class of drugs precisely designed to benefit of this interaction to promote cell death (24) . Since the recent FDA approval of Venetoclax, these molecules are in the spotlight of cancer research, albeit some groups are calling to improve the accurateness of data analysis (54) . A more detailed research in their precise mechanism of action is needed in order to design meaningful combinations for treatment. Nevertheless, we decided to go ahead and test our working hypothesis by designing drug combination testing in vitro. Two BH3-mimetics were chosen: ABT-737, a rather generic compound that, inhibits Bcl-2, Bcl-w and Bcl-x L proteins (55) and A-1331852, a newer and Bcl-x L specific molecule (56) . Neither of them induced a relevant cell death accumulation as monotherapy, but when combined with Dinaciclib they showed a fast synergistic induction of cell death in both SW982 and SK-LMS-1 cells (Figure 5A-B and   Supplementary Figure 4) . The effects were clearly better with A-1331852 than with ABT-737, providing more support to our mechanistic hypothesis. Regretfully, we encountered too many problems at escalating our settings to in vivo experimentation ( Figure 5C-E and Supplementary Figure 5 ). The main issue was the development of deadly liver toxicity, that was already glimpsed in literature (57) . Our data supports the need of more pharmaceutical research in order to generate a safer treatment protocol.
In the past few years, other groups have recognized the potential of BH3-mimetics in combination approaches to kill cancer cells. As previously commented, Inoue-Yamauchi and co-workers, using screening technologies in a small-cell lung cancer model, found that anti-tumor properties of CDK9 inhibitors and anthracyclines were boosted when combined with those molecules (26) . Research in STS has also pointed to the suitability of such combinations. Possible combinations for BH3-mimetics include anthracyclines, histone deacetylase inhibitors, tubulin poisons and etoposide (31, (58) (59) (60) . Here, we add to the list Dinaciclib and Gemcitabine (Figure 5F ) and we point that the major focus should be put in Bcl-x L inhibitors. Both, our data and the previous literature support the conclusion that Bcl-x L targeted molecules behave better than generic BH3-mimetics. The existence of a single molecular route to explain this multiple activity seems unlikely. Bcl-x L has been identified as a key player of cell death triggering after mitotic arrest (50) . This can explain the synergy reported with tubulin poisons or other compounds that induced strong mitotic arrest. But, it is not the case with Dinaciclib, as we obtained no relevant mitotic arrest linked to the cell death triggering. The G 2 blockage reported for SW982 occurs at 72 h and combined cell death is verified at 24 h. Thus, in our setting it is more relevant the quick loss of protein players once Dinaciclib has disturbed the process of protein synthesis. The higher life time of Bcl-x L positions it as the cornerstone of apoptotic induction. For Gemcitabine we cannot discard that the mechanism proceeds more similarly to the observed for mitotic disruptors. In this case, combined action takes more time to be verified (48 h vs.
24 h with Dinaciclib) showing that BH3-mimetics did not exert a pro-apoptotic activity by themselves. Indeed, their function is simply to push towards cell death after another injury has been detected in the cell.
Taking together, we have extensively showed that Dinaciclib (or an improved CDK9 inhibitor) is a suitable candidate for clinical trials in STS. It is capable to effectively kill STS cell lines in a relevant fashion, without inducing a strong selection towards drug resistance. Moreover, when combined with BH3-mimetics its action gets boosted in a remarkable way. Pharmacological research is, however, required in order to address the elevated toxicity linked to this drug. 6 
